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Background: Phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, activated during influenza A virus infection,
can promote viral replication via multiple mechanisms. Direct binding of NS1 protein to p85β subunit of PI3K is
required for activation of PI3K/Akt signaling. Binding and subsequent activation of PI3K is believed to be a
conserved character of influenza A virus NS1 protein. Sequence variation of NS1 proteins in different influenza A
viruses led us to investigate possible deviation from the conservativeness.
Results: In the present study, NS1 proteins from four different influenza A virus subtypes/strains were tested for
their ability to bind p85β subunit of PI3K and to activate PI3K/Akt. All NS1 proteins efficiently bound to p85β and
activated PI3K/Akt, with the exception of NS1 protein from an H5N1 virus (A/Chicken/Guangdong/1/05, abbreviated
as GD05), which bound to p85β but failed to activate PI3K/Akt, implying that as-yet-unidentified domain(s) in NS1
may alternatively mediate the activation of PI3K. Moreover, PI3K inhibitor, LY294002, did not suppress but
significantly increased the replication of GD05 virus.
Conclusions: Our study indicates that activation of PI3K/Akt by NS1 protein is not highly conserved among
influenza A viruses and inhibition of the PI3K/Akt pathway as an anti-influenza strategy may not work for all
influenza A viruses.Background
Influenza A virus continues to pose a severe threat to
poultry farming and human health around the world. To
ensure efficient replication in host cells, influenza virus
manipulates cellular proteins or hijacks important signal-
ing pathways, of which the PI3K/Akt pathway has
received most attention [1,2]. A variety of influenza A
virus strains can activate PI3K/Akt signaling pathway to
support their multiplication [3-6], which is significantly
suppressed by specific PI3K/Akt inhibitors [6-8]. There-
fore, targeting the PI3K/Akt signaling pathway is seen as
an attractive and promising anti-influenza strategy [9].* Correspondence: ksli@stu.edu.cn
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reproduction in any medium, provided the orActivation of PI3K/Akt during influenza A virus infec-
tion can be mediated by diverse mechanisms, such as the
interactions between NS1 proteins of some avian influ-
enza A viruses and cellular proteins Crk/CrkL [10]; dir-
ect binding and activation of Akt by NS1 [11]; as well as
the accumulated viral RNA during the infectious process
[12,13]. However, the most important mechanism re-
sponsible for the activation of PI3K/Akt signaling is the
association between NS1 protein and p85β subunit of
PI3K [3-5,14-17]. In the absence of other viral proteins,
exogenous expression of NS1 derived from different in-
fluenza A virus strains in cells is enough to induce Akt
phosphorylation and activation [3,7,10,16]. In contrast to
influenza A virus NS1 protein (A/NS1), influenza B virus
NS1 protein (B/NS1), which shares less than 20% iden-
tity to A/NS1 in amino acid sequence, naturally lacks the
potential to induce PI3K/Akt signaling [7].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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expressed in influenza virus-infected cells, especially in
the late phase of infection. The average length of NS1
from most influenza A viruses is 230 aa, however, the
length can vary from 202 to 237 aa due to the deletion,
truncation, or addition of amino acids. Besides, amino
acid substitution is also a common event for NS1 pro-
tein, reflecting the evolutionary needs or adaptation of
influenza viruses in different species. Several amino acid
mutations have been shown to alter NS1 function. For
instance, NS1 from different influenza A viruses dis-
played differential binding to CPSF30 (cleavage and poly-
adenylation specificity factor 30 kDa) because of the
residues replacement at positions 103, 106, 108, 125 or
189 [18-20]. Likewise, sequence variation in NS1 may
have variable effects in activating the PI3K/Akt signaling
pathway. To address this hypothesis, four NS1 proteins
from different influenza A virus subtypes/strains were
selected and subjected to a series of comparative ana-
lyses. Our data showed that NS1 protein from an H5N1
virus is unable to activate PI3K/Akt, although it can
interact efficiently with p85β. Additionally, this H5N1
virus exhibited an enhanced replication upon PI3K in-
hibition, highlighting an inner correlation between NS1
variation, PI3K/Akt pathway and virus pathogenicity.
Methods
Cell lines, viruses, and reagents
Madin-Darby canine kidney (MDCK) cells, human lung
carcinoma cell line (A549), and human cervix epithelial
cells (Hela) were routinely cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with anti-
biotics and 10% fetal calf serum at 37°C in 5% CO2.
Influenza A virus strains A/Shantou/169/06(H1N1), A/
Shantou/602/06(H3N2), and A/Chicken/Guangdong/1/
05(H5N1) were used in this study. Viral RNA from A/
Quail/Hong Kong/G1/97 (H9N2) virus was kept in our
lab. The viruses above are abbreviated hereafter to
ST169, ST602, GD05, and Qa97.
QIAamp viral RNA mini kit was purchased from Qiagen
(Hilden, Germany); Trizol reagent and Lipofectamine 2000
from Invitrogen (Carlsbad, CA, USA); AMV reverse tran-
scriptase, PrimeSTAR HS DNA polymerase, restriction
endonucleases, and T4 DNA ligase from TaKaRa (Dalian,
China); plasmid extraction kit and DNA gel purification
kit from Tiangen (Beijing, China); and plasmid pGST-p85β
expressing human p85β from FulenGen (Guangzhou,
China).
Mouse anti-β-actin antibody, rabbit anti-Flag antibody,
and peroxidase-conjugated goat anti-mouse antibody were
from Sigma (St. Louis, MO, USA); rabbit anti-phospho-Akt
(Ser473) antibody and rabbit anti-Akt antibody from Cell
Signaling (Danvers, MA, USA); mouse anti-NS1 antibody
and mouse anti-p85β antibody from Santa Cruz (CA,USA); peroxidase-conjugated goat anti-rabbit antibody and
PI3K inhibitor LY294002 from Beyotime Biotechnology
(Jiangsu, China). Mouse anti-NP antibody was produced in
our laboratory.
Yeast MATCHMAKER GAL4 two-hybrid system 3
and X-α-gal were purchased from Clontech (Palo Alto,
CA, USA); TNT T7 Quick Coupled Transcription/
Translation Systems and Transcend Chemiluminescent
Non-Radioactive Translation Detection Systems were pur-
chased from Promega (Madison, WI, USA); Protein A/G
magnetic beads from New England Biolabs (NEB, Ipswich,
MA, USA); protease inhibitor cocktail from Merck (KGaA,
Germany); protein G-HRP from Genescript (Piscataway,
NJ, USA), and West dura enhanced chemiluminescence
reagents from Pierce (Rockford, IL, USA).
Plasmid construction and confirmation
Full-length NS1 genes from different Influenza A viruses
(A/Shantou/169/2006(H1N1), GeneBank: HQ849876; A/
Shantou/602/2006(H3N2), GeneBank: HQ849877; A/
chicken/Guangdong/1/2005(H5N1), GeneBank: EU874904;
A/Quail/Hong Kong/G1/97(H9N2), GeneBank: AF156477)
were amplified by reverse transcription PCR using viral
RNA and the following primer sets: NS11-S1: 5΄-
AATGGATCCATGGATTCCCACACTGT-3΄ and NS11-
A1: 5΄-TCGGGATCCTCAAACTTCTGACCTAAT-3΄ for
A/Shantou/169/06(H1N1); NS32-S1: 5΄-TA TGGATC
CATGGATTCCAACACTGTG-3΄ and NS32-A1: 5΄-TACG
GATCCTCAAACTTTTGA CCTAGC-3΄ for A/Shantou/
602/06(H3N2); NS51-S1: 5΄-TATGGATCCATGGATTC
CAACACT GTG-3΄ and NS51-A1: 5΄-GACGGATCC
TCAAACTTTTGACTCAATTG-3΄ for A/Chicken/Guang
dong/1/05 (H5N1); and NS92-S1: 5΄-TATGGATCCATG
GATTCCAACACTGTG-3΄ and NS92-A1: 5΄-AGTG
GATCCTCAAACTTCTGGCTCAAT-3΄ for A/Quail/
Hong Kong/G1/97 (H9N2). PCR products were digested
with BamHI and inserted into PNF vector (a modified
pcDNA3 vector with N-terminal Flag tag) or pcDNA3 vec-
tor, giving rise to recombinant plasmids PNF-NS11, PNF-
NS32, PNF-NS51, PNF-NS92, pcDNA3-NS11, pcDNA3-
NS32, pcDNA3-NS51, and pcDNA3-NS92, respectively.
NS11, NS32, NS51, and NS92 are the abbreviations of NS1
protein from H1N1, H3N2, H5N1, and H9N2 viruses. A
plasmid PNF-NS51(I) containing 5 aa insert downstream
of position 79, was constructed as described previously
[21].
To construct NS1-expressing plasmids used for yeast




CACTGTG- 3΄; and NS92-S2: 5΄-CGTGAATTCATG
GATTCCAACACTGTG-3΄. The reverse transcription
PCR reactions were performed using primer sets NS11-S2
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NS32-A1 for A/Shantou/602/06(H3N2), NS51-S2 and
NS51-A1 for A/Chicken/Guangdong/1/05(H5N1), NS92-
S2 and NS92-A1 for A/Quail/Hong Kong/G1/97(H9N2).
PCR products were digested with appropriate enzymes
and cloned into pGADT7 or pGBKT7 vector to yield plas-
mids pGAD-NS11, pGAD-NS32, pGAD-NS51, and
pGAD-NS92, respectively.
To generate plasmid pGBK-p85β, the full-length cod-
ing sequence of human p85β was amplified from plasmid
pGST-p85β using primer sets p85β-S: 5΄-GATGAATT-
CATGGCGGGCCCTGAGG GC-3΄ and p85β-A: 5΄-
TTAGAATTCTCAGCGGGCGGCAGGCGG-3΄ by PCR
and fused into pGBKT7 vector. All of the constructs
were verified by sequencing.
Western blotting
Cells were lysed with 2 × Laemmli sample buffer (contain-
ing 5 mM NaF) in boiling water for 5 min. After brief son-
ication, the lysates were subjected to SDS-PAGE in 10%
polyacrylamide gels and separated proteins were transferred
onto nitrocellulose membranes. Membranes were then
blocked for 1 h in TBST containing 5% nonfat milk and
incubated for 4 h at room temperature with the indicated
antibodies. After extensive washes with TBST, membranes
were exposed to peroxidase-conjugated secondary antibody
(1:3000) for 2 h. Immunoreactive proteins were visualized
using West dura ECL reagent and autoradiography.
Yeast trap assays
Yeast trap assays were performed using the MATCH-
MAKER GAL4 two-hybrid system 3 according to the man-
ufacturer’s instructions. Briefly, AH109 yeast was
transformed with plasmids pGAD-NS11, pGAD-NS32,
pGAD-NS51, and pGAD-NS92 along with pGBK-p85β
and plated onto SD/-Leu/-Trp media (DDO). AH109 yeasts
transformed with plasmids pGBKT7-lam plus pGADT7-T
or pGBKT7-P53 plus pGADT7-T were used as negative
and positive control, respectively. The plates were incu-
bated at 30°C for about 4 days. Fresh AH109 colonies
growing on DDO agar plates were picked and transferred
to SD/-Ade/-His/-Leu/-Trp media containing X-α-gal
(QDO/X-α-gal) followed by incubation at 30°C for 2 or
3 days. The growth and color of colonies was observed
daily. Meanwhile, single AH109 colonies growing on DDO
agar plates were put into liquid DDO media and cultured
at 30°C overnight (~16-18 h) with shaking (250 rpm). The
supernatants were gathered via centrifugation at 14 000 g
for 2 min and subjected to α-galactosidase activity analysis
according to the manufacturer’s protocol.
GST pull-down analysis
Escherichia coli BL21 transformed with pGEX-5x-1 or
pGST-p85β plasmid was grown to mid-log phase andinduced with 0.1 mM IPTG (isopropyl-β-D-thiogalacto-
pyranoside) at 25°C for 4 h. Bacterial pellets were frozen
and thawed for 2 times and lysed with MagneGST lysis
reagent containing DNase, lyticase, and protease inhibi-
tors for 40 min. After centrifugation at 14 000 g for
10 min, the supernatants were incubated with pre-equili-
brated MagneGST beads at 4°C for 30 min. The beads
were then washed 3 times with binding/wash buffer and
the bound GST or GST-p85β was detected by SDS-
PAGE and Coomassie Blue staining.
In vitro translation of different NS1 proteins was per-
formed using pcDNA3-based NS1-expressing plasmids
and TNT T7 Quick Coupled Transcription/Translation
Systems, according to the manufacturer’s instructions.
The translated proteins containing biotinylated lysine
residues in their amino-acid sequence were verified by
Western blot using Streptavidin-HRP.
Next, GST or GST-p85β beads were incubated with
biotinylated NS1 proteins for 2 h at room temperature.
After six washes with binding/wash buffer, bound pro-
teins were resolved by SDS-PAGE, followed by Western
blot analysis with anti-NS1 antibody.Co-immunoprecipitation
Hela cells were transfected with PNF-NS51 plasmid or
PNF empty vector. At 36 h post transfection, cells were
lysed for 20 min on ice in cold NP-40 lysis buffer
(50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1% NP-40,
and protease inhibitor mixture) and centrifuged at 14
000 g for 10 min. Supernatant was precleared by protein
A/G magnetic beads for 1 h. Then, the sample was
mixed with rabbit anti-Flag antibody (1:300) for 2 h at 4°
C with rotation. Normal rabbit IgG was used as a con-
trol. Protein A/G magnetic beads were added to the mix-
ture and incubated overnight at 4°C with gentle rotation.
The beads were washed 3 times with NP-40 lysis buffer,
followed by elution of bound proteins with 2 × Laemmli
sample buffer in boiling water for 5 min. Western blot
analysis was conducted using mouse anti-p85β antibody
(1:750) or mouse anti-NS1 antibody (1:1000) and Protein
G-HRP (1:2500). Immunoblots were developed using
West Dura ECL detection reagents.Viral growth kinetics assays
Serum-starved MDCK cells were pre-treated with 20 μM
LY294002 for 2 h. Different influenza A virus strains
were subsequently added at an MOI (multiplicity of in-
fection) of 0.001. After 1 h of adhesion, the medium was
replaced with serum-free DMEM containing TPCK-tryp-
sin and 20 μM LY294002. Supernatants from infected
cells were collected at various post-infection time points
and titrated by plaque assay in MDCK cells. The experi-
ments were repeated independently 3 times.
Figure 1 Effects of exogenous NS1 proteins on Akt
phosphorylation in different cells. Hela (A, B, C) or A549 cells (D)
were serum-starved for 12 h and transfected with different NS1-
expressing plasmids or PNF empty vector. At 24-h post
transfection, cells were lysed and subjected to Western blot
analysis using the specific antibodies for phospho-Akt(Ser473),
total-Akt, β-actin, or NS1.
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Differential effects of different NS1 proteins on Akt
phosphorylation
Activation of PI3K/Akt pathway has been observed upon
the transfection of plasmids encoding NS1 proteins from a
wide range of influenza A viruses [3,7,10,16]. Moreover,
Akt phosphorylation at serine 473 has been reported to be
PI3K-dependent [22,23]. Therefore we determined the
phosphorylation status of Akt induced by exogenous NS1
proteins from virus strains ST169(H1N1), ST602(H3N2),
Qa97(H9N2), and GD05(H5N1). All NS1 proteins except
NS51 dramatically enhanced phosphorylation of Akt in
Hela cells in our tests (Figure 1a). Especially, NS92 gave
rise to the highest level of Akt phosphorylation, whereas
NS11 and NS32 induced phosphorylation to a lesser de-
gree. To our surprise, NS51 had no effect on the phos-
phorylation level of Akt at Ser473 (Figure 1a). This
phenomenon has not been reported so far for influenza A
virus, except for NS1 from influenza B virus [7].
To rule out the possible influence of Flag tag on NS1
function, pcDNA3-based NS51-expressing plasmid
(without Flag tag) was transfected into Hela cells and
analyzed by Western blotting. The level of phospho-Akt
(Ser473) was the same in both the cells transfected with
pcDNA3-NS51 plasmid and the cells transfected with
pcDNA3 empty vector, being consistent with the above
findings, (Figure 1b).
Deletion of five residues at positions 80–84 of NS1 is a
common phenomenon for most H5N1 viruses isolated
after 2000 [24,25]. We also noticed the same deletion in
our NS51 protein but not in three other NS1 proteins
tested (Figure 2). Thus, we ask whether this deletion
could account for the inability of NS51 to activate Akt
and we found that NS51 protein with five amino acid
inserts still cannot augment the phosphorylation level of
Akt at Ser473 (Figure 1c), suggesting that the failure of
NS51 to stimulate Akt phosphorylation had nothing to
do with this deletion.
To investigate cell type specificity, we further per-
formed phosphorylation assays utilizing the A549 cell (a
widely used human alveolar epithelial cell line in NS1 re-
search) and observed similar results (Figure 1d), indicat-
ing that the differential effects of different NS1 on Akt
phosphorylation were cell type-independent.
Conservative p85β-binding sites in the NS51 protein
The activation of PI3K/Akt is known to be primarily due
to direct interaction between NS1 protein and p85β sub-
unit of PI3K [3-5,14-17]. Since NS51 protein failed to ac-
tivate PI3K/Akt, a reasonable speculation is that NS51
may not interact with p85β. Therefore, we compared the
protein sequence of NS51 to three other NS1 proteins
(Figure 2). Strangely, although NS51 displayed some
amino acid variation to NS11, NS32 and NS92
Figure 2 Sequence alignments of different NS1 proteins. Amino acid sequence alignments of NS1 proteins from different influenza A virus
strains. Numbers correspond to residues in full-length proteins; shadowed boxes denote the key residues (Y89, M93, L141, E142, P162, P164, and
P167) responsible for the binding of NS1 to p85β.
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which are reportedly involved in the interaction between
NS1 and p85β, such as Y89, M93, L141, E142, P162,
P164, and P167 [4,5,16,17], remained unchanged in
NS51 (Figure 2).Yeast trap assays of the association between different
NS1 and p85β
Yeast trap assays were applied to examine the correlation
between NS1 and p85β. For this purpose, four recombin-
ant plasmids (pGAD-NS11, pGAD-NS32, pGAD-NS51,
and pGAD-NS92) were transformed into AH109 yeast
cells in combination with the pGBK-p85β plasmid. The
experimental results showed that, similar to positive con-
trol (pGBKT7-p53 plus pGADT7-T, lane 2 in Figure 3a),
AH109 yeasts harboring each NS1-encoding plasmid and
pGBK-p85β plasmid exhibited vigorous growth and
formed characteristic blue colonies in QDO/X-α-gal
media (lanes 3–6 in Figure 3a), indicating the activation
of reporter gene and the secretion of α-galactosidase in
these yeasts. In contrast, AH109 yeasts in negative con-
trol (pGBKT7-Lam plus pGADT7-T) did not grow on
QDO/X-α-gal media, nor did they produce and secrete
α-galactosidase, as shown by the brown dead yeast cells
(lane 1 in Figure 3a). Quantitative analysis of α-galactosi-
dase activities in liquid DDO media also proved the
comparable level of α-galactosidase generated in experi-
mental groups and positive control (Figure 3b). The
above results suggest that, compared to the other NS1
proteins, NS51 did not display obvious variation in its
binding capacity to p85β in yeast cells.In vitro interaction between NS51 and p85β
Next, we wanted to investigate whether NS51 directly
interacts with p85β in vitro. To this end, GST andGST-p85β were first expressed and purified (Figure 4a),
then the four different NS1 proteins were translated
in vitro (Figure 4b) followed by the GST pull-down assay
(Figure 4c). Our results showed that all four NS1 proteins
have been precipitated by GST-p85β instead of GST, giving
clear evidence of the association between different NS1
proteins and p85β. Therefore, NS51 protein is capable of
binding to p85β in vitro despite its inability to activate
PI3K.In vivo interaction between NS51 and p85β
To further examine whether interaction between NS51
protein and p85β also exists in vivo, we conducted a Co-IP
test and found that Flag antibody precipitated a complex
containing Flag-NS51 and p85β from the lysate of Hela
cells transfected with PNF-NS51 plasmid (Figure 5), indi-
cating a physical association between endogenous p85β
and ectopically expressed NS51 in mammalian cells.Dynamics of Akt phosphorylation during infection of
different influenza A virus strains
Since NS51 did not activate the PI3K/Akt signaling path-
way when exogenously expressed, we further examined its
effect on PI3K/Akt in the infection process. We observed
that all three tested influenza A viruses upregulated
Akt phosphorylation at serine 473 at 2 h postinfection
(Figure 6a, b, and c). Additionally, ST169 and ST602
viruses elicited the second elevation of Akt phosphoryl-
ation around 8 h postinfection (Figure 6a and b). However,
GD05 virus-infected cells did not display increased Akt
phosphorylation at 8 h postinfection, albeit NS51 protein
was markedly expressed at this time point (Figure 6c). The
phosphorylated Akt level even decreased significantly at
12 h postinfection (Figure 6c). We carried out the above
Figure 4 In vitro binding of NS1 proteins with p85β. (A) Expression and purification of GST and GST-p85β protein in E.coli BL21. Purified GST and
GST-p85β proteins were resolved in SDS-PAGE and examined by direct staining with Coomassie Blue; M: molecular weight standard. (B) In vitro
translation of different NS1 proteins using NS1-expressing plasmids and TNT T7 Quick Coupled Transcription/Translation Systems. The in-vitro translated
proteins were identified by Western blot using Streptavidin-HRP as the detecting agent. (C) GST pull-down assay. GST- or GST-p85β-binding magnetic
beads were incubated with NS1 proteins translated in vitro. The bound proteins were subjected to Western blotting with anti-NS1 antibody.
Figure 3 Analysis of the interactions between NS1 proteins and p85β using yeast trap assays. A) AH109 yeasts transformed with the
indicated plasmids were firstly plated onto DDO plates for 4 days of incubation at 30°C. And then, single AH109 colonies were picked and
streaked on QDO/X-α-gal agar plate and incubated at 30°C for 3 days. The representative colonies were presented. (B) Different NS1-encoding
plasmids were transformed into AH109 yeasts together with pGBK-p85β plasmid for α-galactosidase activities assays in liquid culture using PNP-α-
gal as substrate. Data were from three independent experiments. BK-p53 + AD-T and BK-Lam + AD-T represented positive and negative control,
respectively. Statistical comparison of different values was performed by the Student t test. Groups marked with asterisks are statistically different
from the negative group (P< 0.01).
Li et al. Veterinary Research 2012, 43:36 Page 6 of 12
http://www.veterinaryresearch.org/content/1297-9716/43/1/36
Figure 5 In vivo association of NS51 with p85β. Hela cells were
transfected for 36 h with either PNF-NS51 plasmid or PNF empty vector.
Soluble cellular lysates were immunoprecipitated with rabbit anti-Flag
antibody or normal rabbit IgG. Precipitated proteins were separated by
SDS-PAGE, followed by Western blot analysis using mouse anti-NS1
antibody or mouse anti-p85β antibody and Protein G-HRP.
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shown).
UV-inactivated influenza A viruses induced the early
activation of PI3K/Akt pathway
The transient activation of PI3K/Akt at the initial stage of
infection indicates possible dependence on viral attach-
ment and endocytosis but independent of virus replication.
To further clarify this point, influenza viruses were first
inactivated by UV irradiation. UV-inactivated viruses can
not replicate but still retain the receptor-binding and
internalization abilities like wild-type virus [26]. When
these inactivated viruses were added into MDCK cell cul-
tures, as expected, they provoked Akt phosphorylation at
2 h postinfection (Figure 7a, b and c), which was main-
tained for a short time before gradually being reduced with
the advancement of infection (Figure 7a, b, and c).
Suppression of PI3K/Akt pathway imparts different effects
on virus replication
Since NS51 was incompetent to activate PI3K/Akt, we
presumed that the activation of the PI3K/Akt signaling
pathway may be unnecessary for the efficient replication
of GD05 virus. To answer this question, a specific PI3K
inhibitor, LY294002, was used to examine its suppressive
effects on different influenza viruses. ST169 virus exhib-
ited great sensitivity to the treatment of LY294002: rela-
tive to the control, virus yield was decreased by a
maximum 70% in the presence of LY294002 (Figure 8a).
Nevertheless, LY294002 had no obvious influence on the
replication of ST602 virus as virus titers in the experi-
mental groups were comparable to those in the control
groups at all time points tested (Figure 8b). Most import-
antly, LY294002 did not suppress but rather substantially
promoted the replication of GD05 virus. Virus titer
increased up to 5-fold in the LY294002-treated cellscompared to the control cells (Figure 8c). Our data sug-
gest the differential effects of PI3K inhibition on the pro-
liferation of different influenza A virus strains.
Discussion
In the present study, NS11, NS32, and NS92 proteins
(expressed either by transfection or infection) efficiently
activated PI3K/Akt. However, the NS51 protein did not
trigger Akt phosphorylation in both situations (Figures 1
and 6c). Since NS51 had 16.5%, 18.3%, and 12.5% of amino
acid sequence diversity relative to NS11, NS32, and NS92
(Figure 2), the failure of NS51 to activate PI3K could be
caused by its inability to bind the p85β subunit of PI3K
arising from sequence variation. Sequence alignment
results show that crucial sites, which have been reported
to mediate the interaction of NS1 with p85β (Y89, M93,
L141, E142, P162, P164, and P167) [4,5,16,17], are identical
among all tested NS1 proteins (Figure 2, shadowed boxes).
More importantly, yeast trap assays (Figure 3), GST pull-
down (Figure 4) and Co-IP experiments (Figure 5) clearly
indicate the interaction of NS51 with p85β. So it can be
seen that the binding of NS51 to p85β did not lead to the
activation of PI3K/Akt.
PI3K consists of a catalytic subunit (p110) and a regu-
latory subunit (p85β). In the quiescent state, PI3K
remains inactive as the contact between p85β and p110
suppresses the enzymatic activity of p110 [27]. Previous
studies reported that interaction of NS1 and p85β forms
a heterologous NS1-p85β-p110 trimer [14,15,17], in
which NS1 blocks the inhibitory contact between p85β
and p110 and leads to the activation of PI3K [15]. There-
fore, the binding of NS51 with p85β should activate
PI3K. However, this was not the case. NS51 failed to ac-
tivate PI3K, as shown in our experiments (Figures 1 and
6c). So it is much likely that an as-yet-uncharacterized
domain within NS1 could be involved in the activation
of PI3K and amino acid mutations in this domain might
lead to NS51 binding without activating PI3K. Support-
ing evidence from Hale’s study is that two amino acid
mutations at positions 96 and 97 (E96A/E97A) render
loss of PI3K-activating competence of NS1 while retain-
ing its p85β-binding activity [15]. Furthermore, another
study has shown that five amino acid mutations
(GLEWN to RFPRY) at positions 184–188 entirely
deprived the PI3K-activating potential of NS1 [28], which
suggests that the 184–188 residues of NS1 are also
closely related to the activation of PI3K. But we noticed
that E96/E97 (including their flank sequences) as well as
184–188 residues (GLEWN) are considerably conserved
in NS51 and three other NS1 proteins (Figure 2). There-
fore we believe that there is still another region respon-
sible for PI3K activation. We noticed that 5 residues
were missing at positions 80–84 of NS51. Actually, this
deletion in the NS1 protein is a popular event for H5N1
Figure 6 Variation of Akt phosphorylation during influenza A virus infection. Serum- starved MDCK cells were infected with different
influenza A viruses at an MOI of 2. Cells were lysed at indicated postinfection time points and subjected to Western blotting using specific
antibodies for phospho-Akt(Ser473), total-Akt, β-actin, NP, or NS1. Signal intensities of phospho-Akt and total-Akt were quantified by Quantity one
software and the ratios were shown at the bottom.
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know whether it is implicated in the failure of NS51 to
activate PI3K/Akt. Our results show that the missed 5
residues in NS51 were not associated with the activation
of PI3K/Akt (Figure 1c).
In our study, both wild-type and UV-inactivated influ-
enza A viruses provoked transient Akt phosphorylationat the early phase of infection (Figures 6 and 7), implying
that attachment/endocytosis of influenza virus is suffi-
cient for the activation of PI3K/Akt. Similar results
regarding the early activation of PI3K/Akt by wild-type
influenza A or B viruses have also been reported by
others [7,8]. However, it is noteworthy that two inde-
pendent studies by Shin et al. [6] and Hale et al. [4]
Figure 7 Akt phosphorylation at early phase of infection induced by UV-inactivated influenza A viruses. MDCK cells grown in serum-free
medium were infected with UV-inactivated influenza A viruses (MOI = 2) for indicated times. Cellular lysates were used for Western blotting using
specific antibodies for phospho-Akt(Ser473), total-Akt, β-actin, NP, or NS1. Note that no NP proteins were detected except for unspecific bands.
Quantity one software was applied to analyze the signal intensities of phospho-Akt and total-Akt and the relative ratios were presented.
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duce Akt phosphorylation. The reasons for this discrep-
ancy might be that they examined phospho-Akt at the
later time points (6 h postinfection in Shin’s study and
20 h postinfection in Hale’s study) or they used lower
MOI (MOI = 1 in Shin’s study) than we did (MOI = 2).
Moreover, different influenza virus strains or cell types
may contribute to the discrepancy.
Several studies have reported that inhibition of the
PI3K/Akt signaling pathway can significantly suppress
the replication of influenza A viruses [6–8]. Nevertheless,
as was shown in our experiments (Figure 8), differentinfluenza A virus subtypes/strains differed markedly in
their susceptibility to the treatment of PI3K inhibitor
LY294002. Although 20 μM LY294002 repressed the rep-
lication of ST169 virus to a great extent (Figure 8a), it
had no apparent effect on the replication of ST602 virus
(Figure 8b) and even exerted the opposite effect on
GD05 virus (viral titers increased remarkably upon
LY294002 treatment, as seen in Figure 8c). Similar to
our results, Ehrhardt et al. found that, to efficiently sup-
press the replication of A/FPV/Bratislava/79(H7N7), the
working concentration of PI3K inhibitor was
much higher than that required for PR8 suppression
Figure 8 Diverse effects of LY294002 on the replication of different influenza A viruses. Serum-starved MDCK cells were treated with
LY294002 (20 μM) or DMSO at 2 h before and during infection. Then the cells were infected with different influenza A viruses at an MOI of 0.001.
Supernatants were collected at indicated time points and progeny virus titers were subsequently determined by plaque assays and analyzed
statistically by one-way ANOVA (asterisks indicate P< 0.05, NS indicates “not significant”).
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the influence of PI3K/Akt pathway on influenza virus is
strain-specific and PI3K activation by NS1 is not of equal
importance for the efficient replication of different influ-
enza A virus strains. We did not examine the effects of
higher concentrations of LY294002 on influenza A
viruses as they exhibited obvious cytotoxicity in MDCK
cells (data not shown).
The reasons for the aforementioned phenomena may
lie in the dual characters of PI3K/Akt activation. On the
one hand, activation of PI3K/Akt signaling pathway ben-
efits influenza virus replication via multiple diverse
mechanisms, including preventing cellular apoptosis
[3,5,29], promoting viral entry [8], enhancing viral RNA/
protein synthesis or favoring nuclear export of viral RNP
[6]. On the other hand, the anti-viral function of the
PI3K/Akt signaling pathway has also been unraveled by
some studies [30,31]. This is probably because PI3K/Akt
can mediate the signal transduction of native immunity
[8,13,32-35] or enhance expression of anti-viral factors
[36]. Accordingly, we speculate that PI3K inhibitor
LY294002 may simultaneously induce two oppositeeffects (pro- and anti-viral effects) during influenza virus
infection. Its influence on different influenza viruses is
thus determined by which effect is dominant. For the
ST169 virus, an inhibitory effect of LY294002 held the
prevailing position, so viral replication was markedly
suppressed. For ST602 virus, pro- and anti-viral effects
of LY294002 were in balance, thus viral replication was
not apparently affected. As for GD05 virus, although it
stimulated the early activation of PI3K/Akt, it did not in-
duce the late PI3K/Akt activation because of the incom-
petence of NS51. This hints the late PI3K/Akt activation
may not be absolutely essential for the replication of this
virus. Therefore, despite LY294002 treatment, GD05
virus titers were increased due to the inhibition of im-
mune response.
Conclusions
Taken together, activation of the PI3K/Akt signaling
pathway is not a conserved property of influenza A virus
NS1 protein and inhibition of PI3K/Akt is not always fa-
vorable for repression of viral production. Any thera-
peutic measure targeting a virus-induced signaling
Li et al. Veterinary Research 2012, 43:36 Page 11 of 12
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variable antiviral effects due to the numerous subtypes
and very high mutation rate of influenza A virus.
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